Setting Up the Seahorse Glycolysis Stress Test

The instrument reports acidification; the protocol makes it interpretable.

What the Test Measures

The glycolysis stress test injects glucose, then oligomycin, then 2-deoxyglucose, and reports extracellular acidification rate (ECAR) after each step. The three derived parameters are:

ParameterDerived fromWhat it reports
GlycolysisECAR after glucose, minus non-glycolytic acidificationAcidification attributable to glucose metabolism
Glycolytic capacityECAR after oligomycinMaximum acidification when mitochondrial ATP production is blocked
Glycolytic reserveCapacity minus glycolysisThe difference, not a physiological reserve

Important distinction. "Glycolytic reserve" is an arithmetic difference between two assay conditions. It does not mean the cell holds a store of glycolytic capacity that can be called upon in physiology; it means that forcing ATP production through glycolysis raises acidification by that amount. Papers that describe a small reserve as "metabolic inflexibility" are making an interpretive leap.

Readout note. ECAR is extracellular acidification, not glycolysis. Respiratory CO₂ contributes, and in bicarbonate-containing medium the buffering chemistry dominates. The assay is run in a bicarbonate-free, HEPES-buffered medium precisely to reduce that contribution, which also means the cells are outside their normal buffering environment for the duration.

Part 1 — Before the Run

ParameterPractical starting pointWhy it matters
Seeding densityTitrate per cell type; aim for a confluent monolayer at assay timeToo sparse: signal near noise. Too dense: local hypoxia and nonlinearity
Attachment time4–24 h, consistent between platesAttachment stress changes baseline acidification
Assay mediumBicarbonate-free base, HEPES 10–25 mM, glucose-free for the test, glutamine as specifiedSubstrate content defines the baseline
Equilibration45–60 min at 37 °C without CO₂Removes bicarbonate; stabilises pH
Final volumePer the plate format; usually 180–200 µLVolume affects both diffusion and injected concentration
Sensor calibrationPer instrument instructions, same dayDrift masquerades as biology

The first row is the one most often copied from another lab. Density optima differ by several fold between lines, and the correct density is the one that gives a linear relationship between cell number and ECAR in a pilot.

Part 2 — Injection Concentrations

InjectionTypical final concentrationNote
Glucose10 mMSaturating for most lines; check that it is saturating in yours
Oligomycin1 µMTitrate if the response is small; incomplete ATP synthase blockade inflates capacity
2-DG50 mMCompetitive hexokinase inhibition; also affects glycosylation

Caveat on oligomycin. The concentration is chosen to block ATP synthase completely. In cells with high respiratory capacity or high membrane potential, 1 µM may be insufficient, and the resulting "capacity" is an underestimate. A titration in a pilot plate costs three wells and converts the assumption into a measurement.

Caveat on 2-DG. At 50 mM, 2-DG inhibits hexokinase and also interferes with glycosylation, which can induce an ER stress response within the assay window. The post-2-DG ECAR is therefore a lower bound on glycolytic acidification rather than a clean zero.

Part 3 — Cycle Settings

SettingTypicalEffect
Mix3 minEquilibrates the well
Wait2–3 minAllows the sensor to stabilise
Measure3 minAveraged to give the rate
Replicates per condition3–5 wells minimumWell-to-well variance dominates small effects
Baseline cycles before injection3Establishes stability; unstable baselines are a red flag

Readout note. Three baseline cycles before the first injection are diagnostic, not ceremonial. If the three baseline rates differ by more than about 10%, the run should be inspected before interpretation — the cause is usually temperature, bubbles, or incomplete equilibration, and each has a different fix.

Part 4 — Normalisation

BasisStrengthLimitation
Cell count at end of assayDirectRequires counting per well; detachment losses
Total proteinConvenientProtein content changes with treatment
DNALess treatment-sensitive than proteinRequires a reliable assay at low amounts
Pre-assay confluence imagingNon-destructiveIndirect

Normalise to a basis that the treatment does not change. If a drug reduces protein content per cell, protein normalisation will overstate the per-cell effect; if it changes cell number, well-based normalisation is essential.

Part 5 — Common Configuration Errors

  • • Glucose present in the assay medium, which removes the glucose-injection response entirely.
  • • Serum left in the assay medium, which adds substrates and buffering capacity.
  • • Equilibration in CO₂, which leaves bicarbonate in the medium.
  • • Injection volume too large, which dilutes the well and changes the cell environment.
  • • Edge wells used without a layout correction, where evaporation raises effective concentrations.
  • • Compound precipitation in the assay medium, which is common for poorly soluble inhibitors.

Part 6 — Where This Article Connects

The instrument-level companion to the pillar's measurement discussion; the baseline troubleshooting article covers runs that fail to stabilise, and the 2-DG article covers the inhibitor choice in more detail. Interpretation limits — what ECAR can and cannot support — are set out in the pillar and in the glycolytic enzyme article.

If you need glycolysis stress tests with density and oligomycin titration validated for your line, we can scope the work with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Optimal density, injection concentrations and cycle settings vary by cell type, plate format and instrument; the values here are starting points requiring local titration.

ECAR-derived parameters describe acidification under assay conditions, not glycolytic flux in the culture conditions the cells normally experience.

Scientific interpretation and experimental design

  • • ECAR is acidification. The buffer chemistry is part of the measurement.
  • • Reserve is a difference, not a store.
  • • Titrate density. Copied values rarely transfer.
  • • Titrate oligomycin. Incomplete blockade inflates capacity.
  • • 2-DG has a second effect. Glycosylation inhibition within the window.
  • • Three baseline cycles are a diagnostic.

Selected references for further reading

  • • Mookerjee SA, Gerencser AA, Nicholls DG, Brand MD. Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements. Journal of Biological Chemistry. 2017;292:7189–7207.
  • • TeSlaa T, Teitell MA. Techniques to monitor glycolysis. Methods in Enzymology. 2014;542:91–114.
  • • Divakaruni AS, Jastroch M. A practical guide for the analysis, standardization, and interpretation of oxygen consumption measurements. Nature Metabolism. 2022;4:978–994.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: